Advertisement

FGF19 and Cancer

  • Benjamin C. Lin
  • Luc R. Desnoyers
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 728)

Abstract

Fibroblast growth factors (FGFs) and their cognate receptors, FGF receptors (FGFRs), play critical roles in a variety of normal developmental and physiological processes. Numerous reports support a role for deregulation of FGF-FGFR signaling, whether it is at the ligand and/or receptor level, in tumor development and progression. The FGF19-FGFR4 signaling axis has been implicated in the pathogenesis of several cancers, including hepatocellular carcinomas in mice and potentially in humans. This chapter focuses on recent progress in the understanding of the molecular mechanisms of FGF19 action and its potential involvement in cancer.

Keywords

Squamous Cell Carcinoma Hepatocellular Carcinoma Malignant Glioma Lung Squamous Cell Carcinoma Arg388 Allele 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2:REVIEWS3005.Google Scholar
  2. 2.
    Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139–149.PubMedCrossRefGoogle Scholar
  3. 3.
    Sleeman M, Fraser J, McDonald M et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001; 271:171–182.PubMedCrossRefGoogle Scholar
  4. 4.
    Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7:165–197.PubMedCrossRefGoogle Scholar
  5. 5.
    Desnoyers LR, Pai R, Ferrando RE et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27:85–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Nicholes K, Guillet S, Tomlinson E et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160:2295–2307.PubMedCrossRefGoogle Scholar
  7. 7.
    Pai R, Dunlap D, Qing J et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 2008; 68:5086–5095.PubMedCrossRefGoogle Scholar
  8. 8.
    Kurosu H, Choi M, Ogawa Y et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282:26687–26695.PubMedCrossRefGoogle Scholar
  9. 9.
    Lin BC, Wang M, Blackmore C et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007; 282:27277–27284.PubMedCrossRefGoogle Scholar
  10. 10.
    Nishimura T, Utsunomiya Y, Hoshikawa M et al. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1999; 1444:148–151.PubMedGoogle Scholar
  11. 11.
    Xie MH, Holcomb I, Deuel B et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11:729–735.PubMedCrossRefGoogle Scholar
  12. 12.
    Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217–225.PubMedCrossRefGoogle Scholar
  13. 13.
    Choi M, Moschetta A, Bookout AL et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12:1253–1255.PubMedCrossRefGoogle Scholar
  14. 14.
    Asada M, Shinomiya M, Suzuki M et al. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim Biophys Acta 2009; 1790:40–48.PubMedCrossRefGoogle Scholar
  15. 15.
    Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27:3417–3428.PubMedCrossRefGoogle Scholar
  16. 16.
    Harmer NJ, Pellegrini L, Chirgadze D et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43:629–640.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang X, Ibrahimi OA, Olsen SK et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281:15694–15700.PubMedCrossRefGoogle Scholar
  18. 18.
    Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab 2008; 19:239–245.PubMedCrossRefGoogle Scholar
  19. 19.
    Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120–6123.PubMedCrossRefGoogle Scholar
  20. 20.
    Wu X, Ge H, Lemon B et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA 2009; 106:14379–14384.PubMedCrossRefGoogle Scholar
  21. 21.
    Tomiyama K, Maeda R, Urakawa I et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA 2010; 107:1666–1671.PubMedCrossRefGoogle Scholar
  22. 22.
    Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16:179–186.PubMedCrossRefGoogle Scholar
  23. 23.
    Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009; 9:639–651.PubMedCrossRefGoogle Scholar
  24. 24.
    Fausto N. Mouse liver tumorigenesis: models, mechanisms and relevance to human disease. Semin Liver Dis 1999; 19:243–252.PubMedCrossRefGoogle Scholar
  25. 25.
    Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006; 26:385–390.PubMedCrossRefGoogle Scholar
  26. 26.
    Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/ dephosphorylation of beta-catenin. Curr Opin Cell Biol 2005; 17:459–465.PubMedCrossRefGoogle Scholar
  27. 27.
    Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303:1483–1487.PubMedCrossRefGoogle Scholar
  28. 28.
    Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469–480.PubMedCrossRefGoogle Scholar
  29. 29.
    Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science 2000; 287:1606–1609.PubMedCrossRefGoogle Scholar
  30. 30.
    Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837–1851.PubMedGoogle Scholar
  31. 31.
    Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21:1021–1030.PubMedCrossRefGoogle Scholar
  32. 32.
    Wu X, Ge H, Lemon B et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285:5165–5170.PubMedCrossRefGoogle Scholar
  33. 33.
    Ho HK, Pok S, Streit S et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50:118–127.PubMedCrossRefGoogle Scholar
  34. 34.
    Yu C, Wang F, Jin C et al. Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am J Pathol 2002; 161:2003–2010.PubMedCrossRefGoogle Scholar
  35. 35.
    Huang X, Yang C, Jin C et al. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog 2009; 48:553–562.PubMedCrossRefGoogle Scholar
  36. 36.
    Jaakkola S, Salmikangas P, Nylund S et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993; 54:378–382.PubMedCrossRefGoogle Scholar
  37. 37.
    Roidl A, Berger HJ, Kumar S et al. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009; 15:2058–2066.PubMedCrossRefGoogle Scholar
  38. 38.
    Bange J, Prechtl D, Cheburkin Y et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62:840–847.PubMedGoogle Scholar
  39. 39.
    Roidl A, Foo P, Wong W et al. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 2010; 29:1543–1552.PubMedCrossRefGoogle Scholar
  40. 40.
    Spinola M, Leoni V, Pignatiello C et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23:7307–7311.PubMedCrossRefGoogle Scholar
  41. 41.
    Ma Z, Tsuchiya N, Yuasa T et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008; 123:2574–2579.PubMedCrossRefGoogle Scholar
  42. 42.
    Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10:6169–6178.PubMedCrossRefGoogle Scholar
  43. 43.
    Wang J, Yu W, Cai Y et al. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008; 10:847–856.PubMedGoogle Scholar
  44. 44.
    Falvella FS, Frullanti E, Galvan A et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer 2009; 124:2880–2885.PubMedCrossRefGoogle Scholar
  45. 45.
    Sasaki H, Okuda K, Kawano O et al. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol Rep 2008; 20:1125–1130.PubMedGoogle Scholar
  46. 46.
    Ansell A, Farnebo L, Grenman R et al. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 2009; 45:23–29.PubMedCrossRefGoogle Scholar
  47. 47.
    da Costa Andrade VC, Parise O, Jr., Hors CP et al. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82:53–57.PubMedCrossRefGoogle Scholar
  48. 48.
    Streit S, Bange J, Fichtner A et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004; 111:213–217.PubMedCrossRefGoogle Scholar
  49. 49.
    Streit S, Mestel DS, Schmidt M et al. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006; 94:1879–1886.PubMedCrossRefGoogle Scholar
  50. 50.
    Morimoto Y, Ozaki T, Ouchida M et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003; 98:2245–2250.PubMedCrossRefGoogle Scholar
  51. 51.
    Jezequel P, Campion L, Joalland MP et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004; 90:189–193.PubMedCrossRefGoogle Scholar
  52. 52.
    Mawrin C, Kirches E, Diete S et al. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett 2006; 239:239–245.PubMedCrossRefGoogle Scholar
  53. 53.
    Yang YC, Lu ML, Rao JY et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer 2006; 95:1455–1458.PubMedCrossRefGoogle Scholar
  54. 54.
    Matakidou A, El Galta R, Rudd MF et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007; 96:1904–1907.PubMedCrossRefGoogle Scholar
  55. 55.
    Nan H, Qureshi AA, Hunter DJ et al. Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses’ Health Study. BMC Cancer 2009; 9:172.PubMedCrossRefGoogle Scholar
  56. 56.
    Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317:803–806.PubMedCrossRefGoogle Scholar
  57. 57.
    Engstrom W, Granerus M. Effects of fibroblast growth factors 19 and 20 on cell multiplication and locomotion in a human embryonal carcinoma cell line (Tera-2) in vitro. Anticancer Res 2006; 26:3307–3310.PubMedGoogle Scholar
  58. 58.
    Miyake A, Nakayama Y, Konishi M et al. Fgf19 regulated by Hh signaling is required for zebrafish forebrain development. Dev Biol 2005; 288:259–275.PubMedCrossRefGoogle Scholar
  59. 59.
    Siffroi-Fernandez S, Felder-Schmittbuhl MP, Khanna H et al. FGF19 exhibits neuroprotective effects on adult mammalian photoreceptors in vitro. Invest Ophthalmol Vis Sci 2008; 49:1696–1704.PubMedCrossRefGoogle Scholar
  60. 60.
    Thussbas C, Nahrig J, Streit S et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24:3747–3755.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • Benjamin C. Lin
    • 1
  • Luc R. Desnoyers
    • 1
  1. 1.Oncology Biomarker Development/Pharmacodynamic BiomarkersGenentech, Inc.South San FranciscoUSA

Personalised recommendations